番茄社区app

Meeting Coverage

ASH Video Pearls: ALL

Video Pearls from the American Society of Hematology

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone

image

Latest ASH Video Pearls: ALL Meeting Coverage

Chemo-Free Regimen for Ph+ ALL Yields High Rate of Deep MRD Negativity

Ponatinib-blinatumomab led to durable remissions without transplant in most, but 13% relapsed

December 23, 2024
Advances in ALL at ASH Meeting Include New Blinatumomab Data and More

Researchers also examined MRD to guide treatment decisions, and other personalized approaches

December 18, 2024

Latest Oncology/Hematology Meeting Coverage